MicroStrategy, Trump Media, Moderna, Walgreens
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback